Advanced Enzyme Technologies Ltd vs Shilpa Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 402.65 as of 11 May 12:15 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 18.4 on March 2021 to 82.8 on March 2025 . This represents a CAGR of 35.10% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 2721 crore on March 2021 to ₹ 6483 crore on March 2025 . This represents a CAGR of 18.96% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 210.71 crore as compare to the Dec '25 revenue of ₹ 191.66 crore. This represent the growth of 9.94% The revenue of Shilpa Medicare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 410.54 crore. This represent the decline of -100% The ebitda of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 70.57 crore as compare to the Dec '25 ebitda of ₹ 69.07 crore. This represent the growth of 2.17% The ebitda of Shilpa Medicare Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 101.9 crore. This represent the decline of -100% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 45.25 crore over 8 quarters. This represents a CAGR of 13.74% The net profit of Shilpa Medicare Ltd changed from ₹ 14.06 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.86 % on March 2021 to 14.01 % on March 2025 . This represents a CAGR of 23.58% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About Shilpa Medicare Ltd

Shilpa Medicare Limited, formerly known as Shilpa Antibiotics Private Limited was incorporated as a Private Company on November 20, 1987.
The Company changed the status to Public and the name of the Company changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.
It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or Shilpa Medicare Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,999 Cr while Market cap of Shilpa Medicare Ltd is 8,532 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and Shilpa Medicare Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and Shilpa Medicare Ltd?

As of May 11, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹357.3. On the other hand, Shilpa Medicare Ltd stock price is INR ₹436.25.

How do dividend payouts of Advanced Enzyme Technologies Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.